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Abstract
Background: The CONSORT Statement is an evidence-informed guideline for reporting randomised controlled
trials. A number of extensions have been developed that specify additional information to report for more complex
trials. The aim of this study was to evaluate the impact of using a simple web-based tool (WebCONSORT, which
incorporates a number of different CONSORT extensions) on the completeness of reporting of randomised trials
published in biomedical publications.
Methods: We conducted a parallel group randomised trial. Journals which endorsed the CONSORT Statement (i.e.
referred to it in the Instruction to Authors) but do not actively implement it (i.e. require authors to submit a completed
CONSORT checklist) were invited to participate. Authors of randomised trials were requested by the editor to use the
web-based tool at the manuscript revision stage. Authors registering to use the tool were randomised (centralised
computer generated) to WebCONSORT or control. In the WebCONSORT group, they had access to a tool allowing
them to combine the different CONSORT extensions relevant to their trial and generate a customised checklist and
flow diagram that they must submit to the editor. In the control group, authors had only access to a CONSORT flow
diagram generator. Authors, journal editors, and outcome assessors were blinded to the allocation. The primary
outcome was the proportion of CONSORT items (main and extensions) reported in each article post revision.
Results: A total of 46 journals actively recruited authors into the trial (25 March 2013 to 22 September 2015); 324 author
manuscripts were randomised (WebCONSORT n= 166; control n= 158), of which 197 were reports of randomised trials
(n= 94; n= 103). Over a third (39%; n= 127) of registered manuscripts were excluded from the analysis, mainly because the
reported study was not a randomised trial. Of those included in the analysis, the most common CONSORT extensions
selected were non-pharmacologic (n= 43; n= 50), pragmatic (n= 20; n= 16) and cluster (n= 10; n= 9). In a quarter of
manuscripts, authors either wrongly selected an extension or failed to select the right extension when registering their
manuscript on the WebCONSORT study site. Overall, there was no important difference in the overall mean score between
WebCONSORT (mean score 0.51) and control (0.47) in the proportion of CONSORT and CONSORT extension items reported
pertaining to a given study (mean difference, 0.04; 95% CI −0.02 to 0.10).
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Conclusions: This study failed to show a beneficial effect of a customised web-based CONSORT checklist to help authors
prepare more complete trial reports. However, the exclusion of a large number of inappropriately registered manuscripts
meant we had less precision than anticipated to detect a difference. Better education is needed, earlier in the publication
process, for both authors and journal editorial staff on when and how to implement CONSORT and, in particular,
CONSORT-related extensions.
Trial registration: ClinicalTrials.gov: NCT01891448 [registered 24 May 2013].
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Background
Published articles reporting on the methodology and re-
sults of clinical trials are most often, for all readers, the
only way to know how a study was conducted and what
the results were. These articles must present accurate,
unbiased, and transparent information concerning the
methodology and conduct of the trial for the reader to
assess the validity, generalizability, and applicability of
the trial results.
Many studies have evaluated the quality of reporting
in randomised trials in almost every clinical specialty
and subspecialty [1–8]. In nearly every study, the results
indicate that many crucial methodological elements are
not reported in published reports of randomised trials.
For example, in a sample of 616 randomised trials
indexed in PubMed in December 2006, the primary
endpoint was not defined in 47% of trials, the method
used to generate the sequence of randomisation was not
reported in 66%, the method used to conceal allocation
was not reported in 75%, and the sample size calculation
was not reported in 56% [8]. When the tested interven-
tions or studied populations are insufficiently described,
reproducing these interventions is impossible [9], as is
assessing the population to which the results may apply.
Lack of transparency is a major limiting factor for clini-
cians wanting to translate best evidence into best prac-
tice. It is also a major problem for scientists who
perform systematic reviews and meta-analyses as some
published trials may have to be excluded because of
missing information [10, 11].
Lack of transparency [12–14] is mainly the responsi-
bility of the authors of articles, but peer reviewers and
journal editors should ensure that the results are based
on an appropriate methodology. The CONSORT
(CONsolidated Standards of Reporting Trials) Statement,
published in 1996 and updated in 2001 and 2010 [15, 16],
was designed to improve the transparency and quality of
the reporting in clinical trials. It comprises a checklist of
25 items and a flow chart that allows visualisation of the
flow of patients through the study, from recruitment to
the analysis of the results. This recommendation,
endorsed by a considerable number of medical journals,
informs not only authors, but also reviewers and editors,
about which information should be included in articles to
facilitate critical judgment and interpretation of results. A
recent systematic review showed that endorsement of the
CONSORT Statement by a journal was associated with an
improvement in the quality of reporting of randomised
trials [17].
Although the CONSORT Statement applies to all ran-
domised trials, it is primarily appropriate for superiority
trials with two parallel treatment arms and individual
randomisation. Several extensions of the CONSORT
Statement have been developed to specify the additional
information needed in reports of trials with different de-
signs (e.g. non-inferiority [18], cluster randomised [19],
and pragmatic trials [20]) or for specific interventions
(e.g. non-pharmacological treatments [21], acupuncture,
[22] and herbal therapy [23]). Each of these extensions
includes a list of items modified from the original
CONSORT Statement or new items that need to be ad-
dressed when reporting these trials. However, prolifera-
tion of these extensions makes their application difficult
for a specific trial as it involves combining items from
the main CONSORT checklist with those from one or
more extensions. This could be cumbersome and diffi-
cult to apply in practice and so CONSORT may have
limited impact on the reporting quality of these trials.
The objective of this study was to evaluate the impact
of a simple web-based tool (called WebCONSORT,
which incorporates the main CONSORT checklist and
different CONSORT extensions) on the completeness of
reporting of randomised trials published in biomedical
journals. WebCONSORT allows authors to obtain a cus-
tomised CONSORT checklist and flow diagram specific
to their trial design and type of intervention. Our
hypothesis was that this tool would allow optimal use of
the CONSORT Statement and its extensions, thus
leading to an improvement in the transparency of
articles related to randomised trials.
Methods
Design
We conducted a multi-journal, two-arm parallel group,
randomised trial to assess the impact of the WebCON-
SORT tool compared to a control intervention on the
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completeness of reporting of randomised trials submit-
ted to biomedical journals. The study obtained ethics ap-
proval from the University of Oxford Central Research
Ethics Committee, Oxford, UK (MSD-IDREC-C1-2012-89)
and is registered on ClinicalTrials.gov (NCT01891448).
Journal participants
To be eligible for inclusion, journals were required to (1)
endorse the CONSORT Statement (assessed via journal
Instruction to Authors and as listed on the CONSORT
website: www.consort-statement.org); (2) not actively
implement the CONSORT Statement (defined as requir-
ing authors to submit a completed CONSORT checklist
alongside their manuscript at the time of article submis-
sion); and (3) publish reports of randomised trials (cri-
teria assessed February 2013). All journals that met the
above inclusion criteria were sent an email (February
2013) from the WebCONSORT study scientific commit-
tee inviting them to participate in the study. The de-
scription of requirements for participation were included
in the email and study information sheet (Appendix 1)
and editors were asked to verify that they complied with
these criteria and that, while they endorsed the
CONSORT Statement, they do not actively implement it.
If a journal agreed to participate, and confirmed they
met the eligibility criteria, then the journal editor was
asked (Appendix 2) to include an electronic web address
to the WebCONSORT study website in their request for
revision letter to authors for any manuscript identified
by the journal as reporting the results of a randomised
trial. We did this by asking the journal to include this
standard sentence in their revision letter to authors:
“As part of the process of revising your manuscript we
would like you to use the WebCONSORT tool which is
designed to help you improve the reporting of your
randomised trial. You can access the tool by clicking
on the following link: [link to WebCONSORT study
site]. Please be aware that by submitting your
manuscript to our journal it may be part of a research
study, any participation will not impact on any future
acceptance or rejection of your manuscript”.
Participating journals were also informed that we would
require access to the revised manuscript to assess report-
ing quality irrespective of whether it was published or not.
Random assignment
Authors registering on the WebCONSORT study website
were asked to provide some basic information about their
randomised trial. This included the name of the journal
where the manuscript was submitted, the manuscript
number and title, name of submitting author, trial design
(e.g. parallel, cluster, non-inferiority, pragmatic), type of
intervention (e.g. non-pharmacologic, herbal, acupunc-
ture), and number of study groups (arms). Registered
manuscripts were then randomised into two groups (i.e.
WebCONSORT tool or control). The sequence of ran-
domisation was computer generated and stratified by
whether or not a CONSORT extension was relevant. The
assignment was centralised using a web-based system.
Authors and journal editors were blinded to allocation of
the intervention.
Interventions
Construction of the WebCONSORT tool
To construct the WebCONSORT tool (Fig. 1) we first
combined the different CONSORT extensions to allow
grouping of items of similar nature and adaptation of
some items to the 2010 version of the CONSORT State-
ment. Secondly, we designed and built a computerised tool
to allow authors to produce a list of items that must be in-
cluded in the report of their results and a flowchart specific
to their trial. The tool combines the main CONSORT
checklist and extension checklists for different trial designs
(e.g. non-inferiority [18], cluster randomised [19], and
pragmatic trials [20]) and for specific types of interventions
(e.g. non-pharmacological treatments [21], acupuncture
[22], and herbal therapy [23]). The checklist extensions for
Abstracts [24] and Harms [25] were not included because
they are applicable to all trials. The tool automatically gener-
ated a unique list of items customised to a specific trial com-
bining the list of items from the main CONSORT and the
items from all relevant extensions (e.g. for a pragmatic trial
evaluating a non-pharmacological treatment with cluster
randomisation, the main CONSORT checklist was com-
bined with three extensions: pragmatic trial, cluster trial,
and non-pharmacological extensions). This list was gener-
ated based on the description of the trial made by the author
(i.e. type of design and interventions).
A website (Appendix 3: Figure 6) was created where
authors were able to log on and register. Using a
drop-down menu, they could select their precise type
of trial, taking into account the methodological char-
acteristics. Authors were unaware that they were ran-
domised by the software to the WebCONSORT or
control intervention.
Experimental intervention
Authors randomised to the WebCONSORT arm were
directed to a list of CONSORT items specific to their
trial which they could print out. They could also obtain
an automatic flowchart adapted to the design of their
trial. Authors were told that the items generated by the
WebCONSORT tool should be reported in the revised
manuscript and that the completed checklist and flow
diagram should be submitted to the editor. The content
of the WebCONSORT tool was validated by members of
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the study team; this was done by performing a number
of “dummy” randomisations to ensure the correctly
formatted customised checklist was generated based on
different numbers and types of CONSORT extensions
being selected. The WebCONSORT tool website was
also tested by the scientific committee of the study and
by external experts with experience in designing and
conducting clinical trials to ensure the website was clear
and well understood.
Control intervention
Authors randomised to the control group were directed
to a dummy version of the WebCONSORT tool website
which included the customised flow diagram generator
part of the tool but not the main checklist generator or
elements relating to CONSORT extensions.
Outcomes
Our primary outcome was the proportion of the most
important and poorly reported CONSORT Statement
checklist items (main CONSORT and extensions), per-
taining to a given study, reported in the revised manu-
script. For the main CONSORT Statement, a group of
experts, from within the CONSORT Group, identified
the 10 most important and poorly reported CONSORT
checklist items to be assessed for each manuscript, based
on their expert opinion and supported by empirical
evidence where this was available. In addition, the lead
authors of each extension were asked to define the five
Fig. 1 Construction, validation, and evaluation of the WebCONSORT tool
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most important and poorly reported modified items spe-
cific to their extension (Appendix 4: Table 3). As the
number of items differed across trials because the number
of relevant extensions varied, we calculated the percentage
of possible items that were reported for each article.
The secondary outcomes were the mean proportion of
adequately reported items from the main CONSORT
Statement (based on the 10 items for the primary
outcome above), and the mean proportion of adequately
reported items for each of the relevant CONSORT ex-
tensions (based on the five items for the primary out-
come above). We also collected data on the rejection rate
of studies. We had planned to assess the compliance rate
of authors submitting a CONSORT checklist to the
journal and to obtain feedback from authors and journal ed-
itors on the review process; however, these proved difficult
to implement in practice and hence were not assessed.
The evaluation of revised manuscripts was conducted
by a team of 10 reviewers (based at the Centre for Statis-
tics in Medicine, University of Oxford), with statistical
expertise in the design and reporting of clinical trials,
working in pairs who were blinded to the nature of the
study and allocation of the interventions. Each pair
independently extracted data from the manuscripts; any dif-
ferences between reviewers were resolved by discussion,
with the involvement of an arbitrator if necessary. To ensure
consistency between reviewers, we first piloted the data ex-
traction form. We discussed any disparities in the interpret-
ation and modified the data extraction form accordingly.
Sample size
The expected average proportion of adequately reported
items in the control arm was 0.60, and our hypothesis
was that the proportion of adequately reported items
would increase by 25% relatively (15% in absolute value),
thus attaining 0.75 in the experimental arm. Assuming a
common standard deviation of 0.40, 151 articles per arm
were required to demonstrate a significant difference
with a power of 90% (two-sided type 1 error is set at
5%), for a total of 302 articles. This sample size calcula-
tion was based on the assumption that the mean abso-
lute difference is similar in each stratum (whether or not
a CONSORT extension is relevant). We also
hypothesized that clustering by journal would have a
limited impact because we anticipated the number of
journals would be high. Consequently, we did not take
into account the clustering by journal in the sample size
calculation. We did not anticipate that journals would
enroll manuscripts that were not in fact reports of ran-
domised trials.
Fig. 2 Flow of manuscripts registered on the WebCONSORT study website
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Statistical analysis
The main population for analysis were all manuscripts
resubmitted to journals after the intervention occurred,
which was during the revision process of the manuscript.
Statistical analysis was undertaken using STATA IC
(version 13). All outcomes were quantitative and de-
scribed using proportions, mean, standard deviation, and
minimum and maximum values. Quantitative variables
with asymmetric distributions were presented as me-
dians and interquartile ranges. For the primary and sec-
ondary outcomes, we estimated the difference between
means in the two groups with 95% confidence intervals.
The analysis was also stratified according to those arti-
cles which required the inclusion of one or more CON-
SORT extensions and those which did not. Due to the
much larger than anticipated incorrectly specified exten-
sions, we also performed a post-hoc sensitivity analysis
for both primary and secondary outcomes to exclude an
extension from the analysis of a manuscript if it was
wrongly selected by the authors.
Results
Between 25 March 2013 and 22 September 2015, 357
manuscripts were registered on the WebCONSORT
study site from 46 general medical and specialty journals
with an impact factor ranging from 11.34 to 0.65 as of
2014 (Appendix 5: Table 4). Two journals (n = 33 manu-
scripts) subsequently withdrew and were therefore ex-
cluded as we were not able to obtain the revised
manuscripts. Of the remaining 324 registered manu-
scripts, 166 were randomised to the WebCONSORT
tool and 158 to the control intervention; of these, 197
were reports of randomised trials (and we were able to
obtained the revised manuscript) and were included in
the analysis (WebCONSORT n = 94; Control n = 103).
Over a third (39%; n = 127) of registered manuscripts
were excluded from the analysis. Reasons for exclusion
were similar across study arms, the most common rea-
son being that the study was not in fact a report of a
randomised trial (Fig. 2). The percentage of eligible
manuscripts varied considerably across journals (median
73%; IQR 27% to 100%).
Characteristics of manuscripts of randomised trials
Of those included in the analysis (n = 197), the most
common CONSORT extensions selected were non-
pharmacologic (WebCONSORT n = 43; control n = 50),
pragmatic (n = 20; n = 16), cluster (n = 10; n = 9), and
then non-inferiority (n = 9; n = 8), herbal (n = 2; n = 13),
and acupuncture (n = 2; n = 0). Over two-thirds (64%;
72%) of manuscripts were registered as requiring one or
more CONSORT extension. However, for almost a quar-
ter (23%; 21%) of the manuscripts authors either wrongly
selected an extension or failed to select the right
extension when registering their manuscript on the
WebCONSORT study site (Table 1).
Most of the 197 trials were two-arm (WebCON-
SORT 86%; control 82.5%), about half were multicen-
tre (45%; 46.5%), half non-industry funded (50%;
53%), and the median sample size was 98 (IQR, 51 to
180). Around one-third of interventions were drugs
(42.5%; 32%), a third were rehabilitation, psychological
or educational interventions (30%; 36%), and just
under a quarter were surgical or device interventions
(23%; 19%). A CONSORT flow diagram was included
in 85% and 86% of WebCONSORT and control
manuscripts, respectively. Most manuscripts were
Table 1 Number and type of CONSORT extensions (n = 197
manuscripts)
WebCONSORT
(n = 94)
Control
(n = 103)
Number of extensions selecteda
No extension 34 (36%) 29 (28%)
1 extension 37 (40%) 53 (52%)
2 extensions 21 (22%) 20 (19%)
3 extensions 1 (1%) 1 (1%)
4 extensions 1 (1%) 0
Type of extension selectedb
Non-pharmacological extension 43 50
Cluster extension 10 9
Non-inferiority extension 9 8
Pragmatic extension 20 16
Herbal extension 2 13
Acupuncture extension 2 0
Extension correctly matchedc
Yes 72 (77%) 82 (80%)
No 22 (23%) 21 (20%)
Reason for mismatchd
Author wrongly selected:
Pragmatic extension 4 5
Cluster extension 6 4
Non-inferiority extension 3 5
Non-pharmacological extension 2 1
Author failed to select:
Non-pharmacological extension 10 7
Non-inferiority extension 1 0
aNumber of extension(s) selected by the author when registering their
manuscript on the WebCONSORT randomisation site
bType of extension(s) selected by the author when registering their manuscript
on the WebCONSORT randomisation site
cWhether extension(s) selected by the author when registering their
manuscript was assessed as being the appropriate extension
dThere may be more than one reason for a miss match between the extension
selected by the author and the extension which should have been selected
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subsequently published (81%; 84%) in the journal
requesting the revision (Table 2).
Impact of the WebCONSORT tool on reporting of the
revised manuscript
There was no important difference in the overall mean
score (primary outcome) between the WebCONSORT
(mean score 0.51; SD 0.2) and control (mean score 0.47;
SD 0.2) interventions in the proportion of CONSORT
and CONSORT extension items reported pertaining to a
given study (mean difference (MD) 0.04; 95% CI −0.02
to 0.10) (Fig. 3). There was no difference between groups
when the analysis was stratified according to those arti-
cles which were registered as requiring the inclusion of
one or more CONSORT extensions (MD 0.03; 95% CI
−0.03 to 0.09) and those which did not (MD 0.03; 95%
CI −0.07 to 0.13) (Fig. 4), excluding manuscripts for
which an extension wrongly selected by the author had
little impact on the results (MD 0.05; 95% CI −0.01 to
0.11) (Fig. 5). For the secondary outcomes, there was
again minimal difference between groups in the mean
proportion of adequately reported CONSORT items
(based on the 10 items for the primary outcome) (MD
0.03; 95% CI −0.03 to 0.09) or individual CONSORT ex-
tension items (based on the five items for the primary
outcome) when analysed separately (Fig. 3). The percent-
age of adequately reported individual CONSORT and
CONSORT extension items (i.e. cluster, non-inferiority,
pragmatic, non-pharmacologic, acupuncture, herbal) are
given in Appendix 4: Table 3.
Discussion
Principal findings and implications
Our study is the first to evaluate the impact of a simple
web-based intervention (WebCONSORT) that incorpo-
rates the original CONSORT checklist and different
CONSORT extensions, on the completeness of reporting
of randomised trials published in biomedical journals.
Over 40 journals took part in this study, all of which
endorsed the CONSORT Statement in their journal
‘Instruction to Authors’. Our study found no overall
Table 2 General characteristics of manuscripts of randomised
trials (n = 197 manuscripts)
WebCONSORT
(n = 94)
Control
(n = 103)
Trial designa
Cluster 4 (4%) 4 (4%)
Cross over 2 (2%) 4 (4%)
Factorial 0 (0%) 1 (1%)
Non-inferiority 7 (7%) 3 (3%)
Parallel 88 (94%) 94 (97%)
Pragmatic 15 (16%) 11 (11%)
Split body 1 (1%) 0 (0%)
Disease specialty (top five specialties)
Nephrology 13 (14%) 15 (15%)
Gastroenterology 12 (13%) 12 (12%)
Obstetrics & Gynaecology 8 (8.5%) 8 (8%)
Psychiatry & Psychology 5 (5%) 8 (8%)
Oncology 7 (7%) 3 (3%)
Type of intervention
Drug 40 (42.5%) 33 (32%)
Surgery 8 (8.5%) 7 (7%)
Device 14 (15%) 13 (12.5%)
Rehabilitation 5 (5%) 7 (7%)
Psychological 9 (10%) 13 (12.5%)
Education 14 (15%) 17 (16.5%)
Herbal 2 (2%) 13 (12.5%)
Acupuncture 2 (2%) 0
Study centres
Single 45 (48%) 46 (45.5%)
Multi 42 (45%) 48 (46.5%)
Unclear 7 (7%) 9 (9%)
Number of study groups (arms)
2 81 (86%) 85 (82.5%)
3 9 (10%) 12 (11.5%)
4 3 (3%) 6 (6%)
> 4 1 (1%) 0
Median sample size (IQR)
[parallel group only]
108 (54 to 183) 84 (50 to 157)
Funding
Solely industry 10 (11%) 11 (11%)
Part industry 9 (9.5%) 6 (6%)
Non industry 47 (50%) 55 (53%)
Unknown 19 (20%) 24 (23%)
None 9 (9.5) 7 (7%)
Table 2 General characteristics of manuscripts of randomised
trials (n = 197 manuscripts) (Continued)
Flow diagram reported in
revised manuscript
Yes 80 (85%) 89 (86%)
No 14 (15%) 14 (14%)
Manuscript published
Yes 76 (81%) 87 (84%)
No 18 (19%) 16 (16%)
a36/197 (18%) had more than one applicable trial design
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difference between WebCONSORT and the control
intervention in the completeness of reporting of revised
manuscripts. This finding suggests that creating a
customised CONSORT checklist specific to an individual
trial, for use at the revision stage of manuscript submis-
sion, may not optimise the use of CONSORT and its
extensions.
There are several potential reasons why we did not see
an effect of the WebCONSORT intervention. Firstly, all
journals included in our sample already endorsed
CONSORT, thus authors may have felt they complied
with CONSORT guidelines as part of their original sub-
mission; although the low level of reporting seen in our
study suggest this may not be the case. Secondly, it is
possible that the combined customised WebCONSORT
checklist had too many items and was overwhelming for
authors to comply with. There were also no instructions
on how to implement each item in the checklist, sug-
gesting that the checklist alone may not provide suffi-
cient information for most authors. It might be more
effective to focus on a core set of CONSORT items with
more detail about how to implement each item. Thirdly,
it is possible that implementation of a WebCONSORT
tool to improve reporting at the revision stage of a
manuscript once submitted to a journal may be too late.
We may need to intervene earlier in the publication
process and provide more explicit succinct guidance
along with examples of adequate reporting, tailored to
the checklist and context of the trial. COBWEB
(Consort-based WEB tool) is an online writing aid tool
for authors to use when writing up the results of a ran-
domised trial. The tool consists of a series of text boxes
that address CONSORT items, and upon completion the
tool provides a formatted Word document. A rando-
mised trial evaluating the impact of COBWEB found
that the writing aid tool improved the completeness of
manuscripts reporting the results of randomised trials
and therefore may be more effective than the creation
of a customised checklist [26]; the effectiveness of the
writing tool now needs to be tested in a real world
setting [27].
The process of conducting our study produced some
other interesting findings with important implications.
More than one third (39%) of registered manuscripts
were excluded from the analysis as they were not reports
of randomised trials. This was despite clear
Fig. 3 Comparison of overall mean score between WebCONSORT and Control interventions (n = 197 manuscripts)
Fig. 4 Comparison of overall mean score between WebCONSORT and Control interventions stratified by whether or not one or more CONSORT
extensions were selected by the author (n = 197 manuscripts)
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instructions provided to journal editorial staff, and in-
cluded in the revision letter to authors, that only
manuscripts reporting the results of randomised trials
were eligible for inclusion. Clearly, the journal editor-
ial staff at some journals were unable to correctly
identify a randomised trial based on what was re-
ported in the submitted manuscript. Another import-
ant finding is that in a quarter (23%) of manuscripts
authors either selected an inappropriate CONSORT
extension or failed to select the right extension ap-
plicable to their trial when registering their manu-
script on the WebCONSORT study site. A tool to
help authors and journal editors correctly identify the
most appropriate checklist to use when reporting the
results of a study is currently being piloted by the
EQUATOR Network (www.equator-network.org) and
may offer a potential solution.
Comparison with other studies
To our knowledge, our study is the largest rando-
mised trial of its kind, conducted across multiple
journals, evaluating the impact of an intervention to
improve reporting of published research. Other than
the COBWEB study mentioned above [26], very few
randomised trials have been conducted evaluating in-
terventions to improve the quality of reporting. One
randomised trial evaluated the use of the CONSORT
checklist as part of the peer review process and found
this could improve the quality of submitted manu-
scripts [28]; however, this study was only conducted
at a single journal. Previous studies have tended to
explore the impact of the publication of the
CONSORT guidelines and CONSORT extensions by
studying reporting before and after journal endorse-
ment of CONSORT [17], over time (using a time
series analysis) [8, 29] or by monitoring journal en-
dorsement of CONSORT in their ‘Instruction to
Authors’ [30].
Limitations
Our study has several limitations. Firstly, we had to exclude
a number of inappropriately registered studies from the
analysis and, as such, we had less precision than anticipated
to detect a difference between the WebCONSORT inter-
vention and control. Secondly, we do not have information
on the number of manuscripts, at each journal, which were
eligible for inclusion in the study but where the author
chose not to register their manuscript on the WebCON-
SORT study website (and therefore be randomised). Finally,
we do not understand the reasons why authors who regis-
tered their manuscript on the WebCONSORT study web-
site and were randomised to the WebCONSORT
intervention arm did not then address the recommended
checklist items pertaining to their study in their revised
manuscript. Future qualitative research to understand the
potential barriers and facilitators to better implementation
of reporting guidelines would be beneficial.
Conclusion
Twenty years since its first publication, poor adherence to
CONSORT recommendations remains common in pub-
lished reports of randomised trials. Our randomised trial
failed to show a beneficial effect of a customised web-
based CONSORT checklist to help authors prepare more
complete trial reports. However, it is important to note
that the study had less precision than we anticipated to
detect a difference due to the exclusion of a large number
of inappropriately registered manuscripts. These findings
have a number of important implications for future imple-
mentation of CONSORT and reporting guidelines more
generally. There is a clear need for better education much
earlier in the publication process for authors and journal
editorial staff on when and how to implement CONSORT
and, in particular, CONSORT-related extensions. It may
be more effective to focus on a core set of CONSORT
items with more detailed information on how to imple-
ment each item within the context of a specific trial.
Fig. 5 Sensitivity analysis: Comparison of overall mean score between WebCONSORT and Control interventions excluding extensions if wrongly
selected by the author (n = 197 manuscripts)
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Appendix 1
WebCONSORT invitation letter to participating journals
Dear Editor in Chief,
We would like to invite your journal to participate in an
exciting new study which aims to help improve the report-
ing of randomised trials in medical journal articles. We all
know that the reporting of clinical trials is not always opti-
mal, despite the impact of reporting guidelines such as the
CONSORT Statement, and we recognise that it can be a
difficult task for editors to try to improve it.
Our study aims to evaluate whether using a simple web-
based tool (WebCONSORT) improves the reporting of
randomised trials. The tool allows authors of manuscripts
to obtain a customised CONSORT checklist and flow dia-
gram specific to their trial design (e.g. non-inferiority trial,
pragmatic trial, cluster trial) and/or type of intervention
(pharmacological or non-pharmacological).
We are seeking journals willing to collaborate in this
project. The study has been designed so that it will
require only a minimal amount of work on your part
and yet provide a real opportunity to actively contribute
to improving the future reporting of randomised trials,
ultimately having a direct impact on patients and patient
care. We plan to make the WebCONSORT tool freely
available on completion of the study and will of course
acknowledge all participating journals in future
publications.
We have attached a short summary providing you with
more details about the study. If you are interested in
participating or have any questions please register your
interest by responding to this email. We look forward to
hearing from you.
With best wishes
Prof Philippe Ravaud and Dr Sally Hopewell
(Paris Descartes University, France and University of
Oxford, UK)
On behalf of the WebCONSORT Steering Committee:
Prof Doug Altman (University of Oxford, UK), Dr Ginny
Barbour (PLoS Medicine), Prof Isabelle Boutron (Paris
Descartes University, France), Dr Agnes Deschartes
(Paris Descartes University, France), Dr David Moher
(University of Ottawa, Canada), Prof Victor Montori
(Mayo Clinc, USA), Dr David Schriger (Annals of
Emergency Medicine, USA).
This study is supported by the CONSORT Group and
the EQUATOR Network and has been approved by the
University of Oxford Central Research Ethics Committee
MSD-IDREC-C1-2012-89.
Appendix 2
WebCONSORT confirmation letter to participating
journals
Dear [insert editor name]
Thank you very much for agreeing to participate in
this exciting new study which aims to help improve the
reporting of randomised trials in medical journal articles
through the use of a simple web-based tool.
To participate in this study we need you include a
link to the WebCONSORT study website in your
revision letter to authors and you should also notify
authors that their manuscript might be part of a
research study. The easiest way to do this is to in-
clude a standard sentence in your revision letter to
authors, for example:
“As part of the process of revising your manuscript we would
like to use the WebCONSORT tool which is designed to help
you improve the reporting of your randomised trial. You can
access the tool by clicking on the following link: [link to Web-
CONSORT study site].”
“Please be aware that by submitting your manu-
script to our journal it may be part of research study,
any participation will not impact on any future ac-
ceptance or rejection of your manuscript.”
By agreeing to participate in this study, you are
thereby agreeing to allow us access to the revised
manuscript to assess specific aspects of reporting
quality (irrespective of whether the revised manuscript
is published). We will contact you periodically
through the study with details on any manuscripts
registered from your journal. All details of the manu-
script content and the identity of its authors will be
treated in the strictest confidence.
On completion of the study we plan to make the
WebCONSORT tool freely available and will, of
course, acknowledge your journal’s contributions in
future publications. Thank you once again for your
participation in this study, if you have any questions
please do not hesitate to contact us.
With best wishes
Prof Philippe Ravaud and Dr Sally Hopewell
(Paris Descartes University, France and University of
Oxford, UK)
On behalf of the WebCONSORT Steering Committee:
Prof Doug Altman (University of Oxford, UK), Dr Ginny
Barbour (PLoS Medicine), Prof Isabelle Boutron (Paris
Descartes University, France), Dr Agnes Deschartes
(Paris Descartes University, France), Dr David Moher
(University of Ottawa, Canada), Prof Victor Montori
(Mayo Clinc, USA), and Dr David Schriger (Annals of
Emergency Medicine, USA).
This study is supported by the CONSORT Group and
the EQUATOR Network and has been approved by the
University of Oxford Central Research Ethics Committee
MSD-IDREC-C1-2012-89.
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Appendix 3
Fig. 6 Screen shot of WebCONSORT study website
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Appendix 4
Table 3 Percentage of adequately reported individual CONSORT and CONSORT extension items
CONSORT STATEMENT (10 most important and poorly reported CONSORT items assessed) (n = 197 manuscripts)
Item Section CONSORT item Reported WebCONSORT
(n = 94)
Control
(n = 103)
1 Outcomes (6a) Completely defined pre-specified primary outcome
measure, including how and when they were assessed
Yes 68 (72%) 79 (77%)
2 Sample size (7a) How sample size determined Yes 77 (82%) 85 (83%)
3 Sequence generation (8a) Method used to generate random allocation sequence Yes 69 (73%) 78 (76%)
4 Allocation concealment (9) Mechanism used to implement random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence
until interventions were assigned
Yes 60 (64%) 57 (55%)
5 Blinding (11a)* If done, who was blinded after assignment to
interventions (for example, participants care providers
those assessing outcomes)
Yes 44 (47%) 36 (35%)
6 Outcomes and estimation (17a) For the primary outcome, results for each group,
and the estimated effect size and its precision
(such as 95% confidence intervals)
Yes 41 (44%) 45 (44%)
7 Harms (19) All-important harms or unintended effects in each group Yes 63 (67%) 73 (71%)
8 Registration (23) Registration number and name of trial registry Yes 75 (80%) 71 (69%)
9 Protocol (24) Where trial protocol can be assessed, if available Yes 21 (22%) 20 (19%)
10 Funding (25) Sources of funding and other support
(such as supply of drugs) and role of funders
Yes 32 (34%) 35 (34%)
(For combined overall score – analysis blinding not applicable refers to where manuscript states not blinded, so scored as yes = 1)
Flow diagram Reported WebCONSORT
(n = 94)
Control
(n = 103)
(flow diagram reported in revised manuscript) Yes 80 (85%) 89 (86%)
Participant flow (13a) For each group, the numbers of participants
randomly assigned,
Yes 87 (93%) 99 (96%)
received intended treatment, and were analysed
for the primary outcome
Yes 68 (72%) 82 (80%)
Yes 81 (86%) 88 (85%)
(13b) For each group, losses and exclusions after
randomisation, together with reason
Yes 83 (88%) 87 (84%)
CONSORT DESIGN EXTENSIONS (five most important and poorly reported CONSORT items assessed per extension)
Cluster trials extension selected (n=19 manuscripts)
Section Extension item Reported WebCONSORT
(n = 10)
Control
(n = 9)
1 Background and objectives (2a) Rationale for using cluster design Yes 3 (30%) 3 (33%)
2 Sample size (7a) Method of calculation, number of cluster(s)
(and whether equal or unequal cluster
sizes are assumed), a coefficient of intra-cluster
correlation (ICC or k), and an indication
of its uncertainty
Yes 2 (20%) 1 (11%)
3 Randomisation (10b) Mechanism by which individual participants
were included in clusters for the purposes of
the trial (such as complete enumeration,
random sampling)
Yes 3 (30%) 0 (0%)
4 Statistical methods (12a) How clustering was taken into account Yes 4 (40%) 3 (33%)
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Table 3 Percentage of adequately reported individual CONSORT and CONSORT extension items (Continued)
5 Outcomes and estimation (17a) Results at individual or cluster level as applicable
and a coefficient correlation of ICC or k for each
primary outcome
Yes 0 (0%) 1 (11%)
Non-inferiority trials extension selected (n = 17 manuscripts)
Section Extension item Reported WebCONSORT
(n = 9)
Control
(n = 8)
1 Background and objectives
(2a & b)
Rationale for using a non-inferiority design
Hypothesis concerning non inferiority, specifying
the non-inferiority margin with the rationale
for its choice
Yes 2 (22%) 1 (12%)
2 Interventions (5) Whether the reference treatment in the
non-inferiority trial is identical (or very similar)
to that in any trial(s) that established efficacy
Yes 4 (44%) 0 (0%)
3 Sample size (7a) Whether the sample size was calculated
using non inferiority criterion and, if so,
what the non-inferiority margin was
Yes 5 (55%) 3 (37.5%)
4 Statistical methods (12a) Whether a one- or two-sided confidence
interval approach was used
Yes 5 (56%) 4 (50%)
5 Outcomes and estimation (17a) For the outcome(s) for which non-inferiority
was hypothesized, a figure showing confidence
intervals and the non-inferiority margin may
be useful
Yes 2 (22%) 1 (12%)
Pragmatic trials extension selected (n = 36 manuscripts)
Section Extension item Reported WebCONSORT
(n = 20)
Control
(n = 16)
1 Participants (3) Eligibility criteria should be explicitly framed
to show the degree to which they include
typical participants and/or where applicable,
typical providers (e.g. nurses), institutions
(e.g. hospitals), communities (or localities,
e.g. towns) and settings of care (e.g. different
healthcare financing systems)
Yes
NA
7 (35%)
1 (5%)
2 (12.5%)
3 (19%)
2 Interventions (4) Describe extra resources added to (or resources
removed from) usual settings in order to
implement intervention; indicate if efforts
were made to standardise the intervention
or if the intervention and its delivery were
allowed to vary between participants,
practitioners, or study sites; describe the
comparator in similar detail to the intervention
Yes 7 (35%) 4 (25%)
3 Outcomes (6) Explain why the chosen outcomes are
considered important to those who will use
the results of the trial and, when relevant,
why the length of follow-up is considered
important to those who will use the results
of the trial
Yes 2 (10%) 3 (19%)
4 Sample size (7) If calculated using the smallest difference
considered important by the target decision
maker audience (the minimally clinically
important difference) then report where
this difference was obtained
Yes 4 (20%) 3 (19%)
5 Blinding (11) If blinding was not done, or was not
possible, explain why
Yes 4 (20%) 2 (12.5%)
CONSORT INTERVENTION EXTENSIONS (top five items per extension)
Non-pharmacologic extension selected (n = 93 manuscripts)
Section Extension item Reported WebCONSORT
(n = 43)
Control
(n = 50)
1 Participants (3) When applicable, eligibility criteria for
centres and those performing the interventions
Yes
NA
6 (14%)
18 (42%)
4 (8%)
22 (44%)
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Table 3 Percentage of adequately reported individual CONSORT and CONSORT extension items (Continued)
2 Interventions (4a, b, c) a) Description of the different components
of the interventions and, when applicable,
description of the procedure for tailoring
the interventions to individual participants
b) Details of how the interventions were
standardised
c) Details of how adherence of care providers
with the protocol was assessed or enhanced
Yes 4 (9%) 2 (4%)
3 Sequence generation (8) When applicable, how care providers were
allocated to each trial group
Yes
NA
6 (14%)
20 (47%)
3 (6%)
30 (60%)
4 Statistical methods (12) When applicable, details of whether and
how clustering by care providers or centres
was addressed
Yes
NA
4 (9%)
35 (81%)
5 (10%)
36 (72%)
5 Baseline data (15) When applicable, a description of care
providers (case volume, qualification,
expertise, etc.) in each group and centres
(volume) in each group
Yes
NA
4 (9%)
9 (21%)
5 (10%)
18 (36%)
Acupuncture extension selected (n = 2 manuscripts)
Section Extension item Reported WebCONSORT
(n = 2)
Control
(n = 0)
1 Intervention: Details
of needling (2b)
Names (or location if no standard name)
of points used (uni/bilateral)
Yes 2 (100%) 0
2 (2c) Depth of insertion, based on a specified unit
of measurement, or on a particular tissue level
Yes 2 (100%) 0
3 (2d) Response sought (e.g. de qi or muscle
twitch response)
Yes 1 (50%) 0
4 (2e) Needle stimulation (e.g. manual, electrical) Yes 2 (100%) 0
5 (2f) Needle retention time Yes 1 (50%) 0
Herbal extension selected (n = 15 manuscripts)
Section Extension item Reported WebCONSORT
(n = 2)
Control
(n = 13)
1 Intervention: Herbal
medicinal product
name (4a)
The Latin binomial name together with
botanical authority and family name for
each herbal ingredient; common name(s)
should also be included; the proprietary
product name (i.e. brand name) or the
extract name (e.g. EGb-761) and the name
of the manufacturer of the product; whether
the product used is authorised (licensed,
registered) in the country in which the
study was conducted.
Yes 1 (50%) 5 (38%)
2 Characteristics of the
herbal product (4b)
The part(s) of plant used to produce the
product or extract. The type of product
used (e.g. raw [fresh or dry], extract); the
type and concentration of extraction solvent
used (e.g. 80% ethanol, 100% H2O, 90%
glycerin, etc.) and the ratio of herbal drug
to extract (e.g. 2 to 1); the method of
authentication of raw material (i.e. how
done and by whom) and the lot number
of the raw material
Yes 0 0
3 Dosage regimen
and quantitative
description (4c)
The dosage of the product, the duration
of administration and how these were
determined; the content (e.g. as weight,
concentration; may be given as range
where appropriate) of all quantified herbal
product constituents, both native and added,
Yes 0 2 (15%)
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per dosage unit form; added materials,
such as binders, fillers, and other excipients
(e.g. 17% maltodextrin, 3% silicon dioxide
per capsule), should also be listed
4 Qualitative testing (4d) Product’s chemical fingerprint and methods
used (equipment and chemical reference standards)
and who performed the chemical analysis
(e.g. the name of the laboratory used); whether
a sample of the product (i.e. retention sample)
was retained and if so, where it is
Kept or deposited; description of any special
testing/purity testing (e.g. heavy metal or other
contaminant testing) undertaken, which
unwanted components were removed
and how (i.e. methods)
Standardization: what to standardise
(e.g. which chemical components of the product)
and how (e.g. chemical processes
or biological/functional measures of activity)
Yes 0 0
5 Practitioner (4f) Description of practitioners (e.g. training
and practice experience) part of the intervention
Yes 0 0
Table 4 Impact factor of journals participating in the WebCONSORT
study
Journal Impact factor
(as of 2014)
American Journal of Kidney Diseases 5.90
Annals of Surgery 8.32
Arquivos Brasileiros 1.02
BMC Anesthesiology 1.37
BMC Cancer 3.36
BMC Endocrine Disorders 1.71
BMC Family Practice 1.67
BMC Gastroenterology 2.36
BMC Health Services Research 1.71
BMC Infectious Diseases 2.61
BMC Medicine 7.25
BMC Nursing –
BMC Oral Health 1.13
BMC Public Health 2.26
BMC Surgery 1.39
British Journal of Geriatrics –
British Journal of Obstetrics and Gynaecology 3.73
British Journal of Surgery 5.54
Canadian Medical Association Journal 5.96
Child and Adolescent Psychiatry and Mental Health 2.14
Chinese Medicine 1.49
Conflict and Health –
Critical Care 4.48
Table 4 Impact factor of journals participating in the WebCONSORT
study (Continued)
Indian Journal of Dermatology 1.34
International Journal of Nursing Studies 2.90
International Journal of Paediatric Dentistry 1.34
Journal of Advanced Nursing 1.74
Journal of Cardiothoracic Surgery 1.04
Journal of Genetic Counseling 2.24
Journal of Gynecologic Oncology 2.49
Journal of Hand Surgery 2.04
Journal of Hepatology 11.34
Journal of the American Podiatric Medical Association 0.65
NIHR HTA monograph 5.12
Neurourology and Urodynamics 2.87
Nordic Journal of Music Therapy 0.96
Orphanet Journal of Rare Diseases 3.36
Pediatric Pulmonology 2.70
Peritoneal Dialysis International 1.53
Physiotherapy 1.91
Public Health Nutrition 2.68
Thrombosis and Haemostasis 4.98
Hopewell et al. BMC Medicine  (2016) 14:199 Page 15 of 17
Surgery; British Journal of Geriatrics; British Journal of Obstetrics and
Gynaecology; British Journal of Surgery; Canadian Medical Association
Journal; Child and Adolescent Psychiatry and Mental Health; Chinese
Medicine; Conflict and Health; Critical Care; Indian Journal of
Dermatology; International Journal of Nursing Studies; International
Journal of Paediatric Dentistry; Journal of Advanced Nursing; Journal of
Cardiothoracic Surgery; Journal of Genetic Counseling; Journal of
Gynecologic Oncology; Journal of Hand Surgery; Journal of Hepatology;
Journal of the American Podiatric Medical Association; NIHR HTA
monograph; Neurourology and Urodynamics; Nordic Journal of Music
Therapy; Orphanet Journal of Rare Diseases; Pediatric Pulmonology;
Peritoneal Dialysis International; Physiotherapy; Public Health Nutrition;
and Thrombosis and Haemostasis.
Funding
This study received funding from the French Ministry for Health. The funder
had no role in the design, conduct, analysis or reporting of this study.
Authors’ contributions
SH, IB, DA, PR, GB, DM, DS, and VM were involved in the design, implementation,
and analysis of the study, and in writing the final manuscript. JC, SG, OO, PD, CR, EF,
LC, VC, and IR were involved in the implementation of the study and in
commenting on drafts of the final manuscript. SH is responsible for the overall
content as guarantor. All authors read and approved the final manuscript.
Competing interests
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/
coi_disclosure.pdf and declare no support from any organisation for the submitted
work, no financial relationships with any organisations that might have an interest
in the submitted work in the previous three years, and no other relationships or
activities that could appear to have influenced the submitted work.
Ethics approval
The study obtained ethics approval from the University of Oxford Central
Research Ethics Committee, Oxford, UK (MSD-IDREC-C1-2012-89).
Transparency
The lead author (the manuscript’s guarantor) affirms that the manuscript is an
honest, accurate, and transparent account of the study being reported, that no
important aspects of the study have been omitted, and that any discrepancies
from the study as planned (and, if relevant, registered) have been explained.
Data sharing
Anonymous data are available on request.
Author details
1Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
2Centre for Statistics in Medicine, Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
3Centre d’Epidémiologie Clinique, Paris Descartes University, Paris, France.
4INSERM UMR 1153 equipe Methods, Paris Descartes University, Paris, France.
5Queensland University of Technology (QUT), Queensland, Australia. 6Ottawa
Hospital Research Institute, Ottawa, Canada. 7Mayo Clinic, Minnesota, USA.
8University of California, Los Angeles, USA.
Received: 5 September 2016 Accepted: 28 October 2016
References
1. Agha R, Cooper D, Muir G. The reporting quality of randomised controlled
trials in surgery: a systematic review. Int J Surg. 2007;5(6):413–22.
2. Chan AW, Altman DG. Epidemiology and reporting of randomised trials
published in PubMed journals. Lancet. 2005;365(9465):1159–62.
3. Gibson CA, Kirk EP, LeCheminant JD, Bailey Jr BW, Huang G, Donnelly JE.
Reporting quality of randomized trials in the diet and exercise literature for
weight loss. BMC Med Res Methodol. 2005;5:9.
4. Jacquier I, Boutron I, Moher D, Roy C, Ravaud P. The reporting of randomized
clinical trials using a surgical intervention is in need of immediate
improvement: a systematic review. Ann Surg. 2006;244(5):677–83.
5. Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin
lymphoma in biomedical journals. J Natl Cancer Inst. 2006;98(9):620–5.
6. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial
reporting in leading medical journals since the revised CONSORT statement.
Contemp Clin Trials. 2005;26(4):480–7.
7. Moberg-Mogren E, Nelson DL. Evaluating the quality of reporting
occupational therapy randomized controlled trials by expanding the
CONSORT criteria. Am J Occup Ther. 2006;60(2):226–35.
8. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. The quality of reports
of randomised trials in 2000 and 2006: comparative study of articles
indexed in PubMed. BMJ. 2010;340:c723.
9. Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from
descriptions of treatment in trials and reviews? BMJ. 2008;336(7659):1472–4.
10. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical
evidence for selective reporting of outcomes in randomized trials:
comparison of protocols to published articles. JAMA. 2004;291(20):2457–65.
11. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in
randomized trials funded by the Canadian Institutes of Health Research.
CMAJ. 2004;171(7):735–40.
12. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality
of reports of randomised trials affect estimates of intervention efficacy
reported in meta-analyses? Lancet. 1998;352(9128):609–13.
13. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias.
Dimensions of methodological quality associated with estimates of
treatment effects in controlled trials. JAMA. 1995;273(5):408–12.
14. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical
evidence of bias in treatment effect estimates in controlled trials with
different interventions and outcomes: meta-epidemiological study. BMJ.
2008;336(7644):601–5.
15. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ,
et al. CONSORT 2010 explanation and elaboration: updated guidelines for
reporting parallel group randomised trials. BMJ. 2010;340:c869.
16. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
17. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the
CONSORT Statement impact the completeness of reporting of randomised
controlled trials published in medical journals? A Cochrane review. Syst Rev.
2012;1:60.
18. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of
noninferiority and equivalence randomized trials: extension of the CONSORT
2010 statement. JAMA. 2012;308(24):2594–604.
19. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement:
extension to cluster randomised trials. BMJ. 2012;345, e5661.
20. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al.
Improving the reporting of pragmatic trials: an extension of the CONSORT
statement. BMJ. 2008;337:a2390.
21. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the
CONSORT statement to randomized trials of nonpharmacologic treatment:
explanation and elaboration. Ann Intern Med. 2008;148(4):295–309.
22. MacPherson H, Altman DG, Hammerschlag R, Youping L, Taixiang W, White A,
et al. Revised STandards for Reporting Interventions in Clinical Trials of
Acupuncture (STRICTA): extending the CONSORT statement. PLoS Med. 2010;
7(6), e1000261.
23. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting
randomized, controlled trials of herbal interventions: an elaborated
CONSORT statement. Ann Intern Med. 2006;144(5):364–7.
24. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al.
CONSORT for reporting randomized controlled trials in journal and
conference abstracts: explanation and elaboration. PLoS Med. 2008;5(1), e20.
25. Ioannidis JP, Evans SJ, Gotzsche PC, O’Neill RT, Altman DG, Schulz K, et al.
Better reporting of harms in randomized trials: an extension of the
CONSORT statement. Ann Intern Med. 2004;141(10):781–8.
26. Barnes C, Boutron I, Giraudeau B, Porcher R, Altman DG, Ravaud P.
Impact of an online writing aid tool for writing a randomized trial
report: the COBWEB (Consort-based WEB tool) randomized controlled
trial. BMC Med. 2015;13:221.
27. Marusic A. A tool to make reporting checklists work. BMC Med. 2015;13:243.
28. Cobo E, Cortes J, Ribera JM, Cardellach F, Selva-O’Callaghan A, Kostov B,
et al. Effect of using reporting guidelines during peer review on quality of
final manuscripts submitted to a biomedical journal: masked randomised
trial. BMJ. 2011;343:d6783.
Hopewell et al. BMC Medicine  (2016) 14:199 Page 16 of 17
29. Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors’ implementation
of CONSORT guidelines on the reporting of abstracts in high impact
medical journals: interrupted time series analysis. BMJ. 2012;344:e4178.
30. Shamseer L, Hopewell S, Altman DG, Moher D, Schulz KF. Update on the
endorsement of CONSORT by high impact factor journals: a survey of
journal “Instructions to Authors” in 2014. Trials. 2016;17:301.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hopewell et al. BMC Medicine  (2016) 14:199 Page 17 of 17
